https://ir.opusgtx.com/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_3f85a7dcbfea56422a5e0fee0b561249/ocuphire/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.opusgtx.com/press-releases/detail/525/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting Fri, 10 Apr 26 06:59:00 -0400 https://ir.opusgtx.com/press-releases/detail/525/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting https://ir.opusgtx.com/press-releases/detail/524/opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland-capital Mon, 06 Apr 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/524/opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland-capital https://ir.opusgtx.com/press-releases/detail/523/opus-genetics-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026 Tue, 24 Mar 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/523/opus-genetics-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026 https://ir.opusgtx.com/press-releases/detail/522/opus-genetics-announces-financial-results-for-full-year-2025-and-provides-corporate-update Tue, 10 Mar 26 07:00:00 -0400 https://ir.opusgtx.com/press-releases/detail/522/opus-genetics-announces-financial-results-for-full-year-2025-and-provides-corporate-update https://ir.opusgtx.com/press-releases/detail/521/opus-genetics-to-present-at-upcoming-investor-conferences-in-march-2026 Tue, 03 Mar 26 08:00:00 -0500 https://ir.opusgtx.com/press-releases/detail/521/opus-genetics-to-present-at-upcoming-investor-conferences-in-march-2026 https://ir.opusgtx.com/press-releases/detail/520/opus-genetics-announces-initial-clinical-data-from-phase-12-opgx-best1-gene-therapy-study-at-the-macula-society-annual-meeting Fri, 27 Feb 26 10:10:00 -0500 https://ir.opusgtx.com/press-releases/detail/520/opus-genetics-announces-initial-clinical-data-from-phase-12-opgx-best1-gene-therapy-study-at-the-macula-society-annual-meeting https://ir.opusgtx.com/press-releases/detail/519/opus-genetics-announces-fda-acceptance-of-supplemental-new-drug-application-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia Wed, 25 Feb 26 06:59:00 -0500 https://ir.opusgtx.com/press-releases/detail/519/opus-genetics-announces-fda-acceptance-of-supplemental-new-drug-application-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia https://ir.opusgtx.com/press-releases/detail/518/opus-genetics-announces-25-million-private-placement Fri, 13 Feb 26 07:30:00 -0500 https://ir.opusgtx.com/press-releases/detail/518/opus-genetics-announces-25-million-private-placement https://ir.opusgtx.com/press-releases/detail/517/opus-genetics-to-participate-in-upcoming-medical-and-industry-conferences-in-february-2026 Mon, 02 Feb 26 08:00:00 -0500 https://ir.opusgtx.com/press-releases/detail/517/opus-genetics-to-participate-in-upcoming-medical-and-industry-conferences-in-february-2026 https://ir.opusgtx.com/press-releases/detail/516/opus-genetics-launches-gene-therapy-clinical-trial-for-mertk-related-retinitis-pigmentosa Tue, 27 Jan 26 07:00:00 -0500 https://ir.opusgtx.com/press-releases/detail/516/opus-genetics-launches-gene-therapy-clinical-trial-for-mertk-related-retinitis-pigmentosa